The Nomination Committee consists of:

• Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties’ holdings
• Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund
• Katarina Hammar, appointed by Nordea Funds
• Elisabet Jamal Bergström, appointed by SEB Funds
• Robin Nestor, appointed by Lannebo Kapitalförvaltning

The Nomination Committee will appoint one of its members as Chairman.
  
Shareholders wishing to submit proposals to Elekta’s Nomination Committee can do so by e-mail to peter.nyquist@elekta.com or by letter to:

Elekta AB (publ)
Att: Nomination Committee
P.O. Box 7593
SE-103 93 Stockholm
Sweden

In order for the Nomination Committee to be able to process any proposals constructively, these should be received by the Nomination Committee no later than June 5, 2026.

# # #

For further information, please contact:
Peter Nyquist, Vice President Investor Relations
Tel: +46 70 424 6127, e-mail: peter.nyquist@elekta.com
Time zone: CET: Central European Time

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com.